PhaseBio Pharmaceuticals, Inc. Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes
6/4/2013 10:16:42 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company focused on diabetes and cardiovascular diseases, today announced that it has initiated the first Phase 1 study for development of PE0139, a novel long-acting basal insulin, for the treatment of Type 2 diabetes.
Help employers find you! Check out all the jobs and post your resume.
comments powered by